Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Accumulated Depreciation (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Accumulated Depreciation for 6 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 1.5% to $7.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.4 million through Dec 2025, up 1.5% year-over-year, with the annual reading at $7.4 million for FY2025, 1.5% up from the prior year.
  • Accumulated Depreciation hit $7.4 million in Q4 2025 for Bolt Biotherapeutics, up from $7.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $7.4 million in Q4 2025 to a low of $1.5 million in Q1 2021.
  • Historically, Accumulated Depreciation has averaged $4.8 million across 5 years, with a median of $5.1 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation: soared 81.19% in 2021 and later increased 1.5% in 2025.
  • Year by year, Accumulated Depreciation stood at $2.2 million in 2021, then skyrocketed by 74.39% to $3.9 million in 2022, then soared by 46.92% to $5.8 million in 2023, then rose by 26.53% to $7.3 million in 2024, then increased by 1.5% to $7.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation for BOLT at $7.4 million in Q4 2025, $7.1 million in Q3 2025, and $6.8 million in Q2 2025.